The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors
- 27 June 2007
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 194 (3) , 347-359
Abstract
Rationale Nonselective muscarinic acetylcholine antagonists have been used for several years as antiparkinsonian drugs. However, there are at least five subtypes of muscarinic receptor (M1–5). Neostriatal M4 receptors have been implicated in aspects of motor function, and it has been suggested that M4 antagonists could be used as treatments for parkinsonism. Objective Currently, there is a lack of highly selective M4 antagonists that readily penetrate the blood brain barrier. Thus, the present studies focused upon the effects of tropicamide, a muscarinic acetylcholine receptor antagonist with moderate binding selectivity for the M4 receptor subtype. Materials and methods Tremulous jaw movements were used as a model of parkinsonian tremor in these studies, and the effects of tropicamide were compared with those of the nonselective muscarinic antagonist atropine. Results Tropicamide suppressed the tremulous jaw movements induced by the muscarinic agonist pilocarpine and the dopamine antagonist pimozide. Analysis of the dose–response curves indicated that tropicamide showed approximately the same potency as atropine for suppression of pilocarpine-induced jaw movements but was more potent than atropine on the suppression of pimozide-induced jaw movements. In contrast, atropine was more potent than tropicamide in terms of impairing performance on visual stimulus detection and delayed nonmatch-to-position tasks. Conclusions These studies demonstrate that tropicamide, which currently is used clinically for ophthalmic purposes, can exert actions that are consistent with antiparkinsonian effects. Moreover, the different pattern of effects shown by tropicamide compared to those of atropine on motor vs cognitive tasks could be due to the modest M4 selectivity shown by tropicamide.Keywords
This publication has 110 references indexed in Scilit:
- Rationale for current therapies in Parkinson’s diseaseExpert Opinion on Pharmacotherapy, 2003
- Double‐blind, single‐dose, cross‐over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's diseaseMovement Disorders, 2002
- Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre studyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Rigidity decreases resting tremor intensity in Parkinson's disease: A [123I]β‐CIT SPECT study in early, nonmedicated patientsMovement Disorders, 2001
- Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodentsLife Sciences, 2001
- Spontaneously hypertensive rats cholinergic hyper‐responsiveness: central and peripheral pharmacological mechanismsBritish Journal of Pharmacology, 1999
- Molecular Biology of Muscarinic Acetylcholine ReceptorsCritical Reviews™ in Neurobiology, 1996
- Effects of Chlordiazepoxide and Scopolamine, But Not Aging, on the Detection and Identification of Conditional Visual StimuliThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1995
- Modelling working and reference memory in ratsBehavioural Pharmacology, 1990
- Behavioural functions of nucleus basalis magnocellularis and its relationship to dementiaTrends in Neurosciences, 1986